GLP-1 weight loss plateaus: what the science says about stalls

What did @katasky actually say?

@katasky, who says she has lost 275 pounds, made the case that weight loss stalls are a universal experience, even on GLP-1 medications. Her core message: "weight loss isn't a straight line, it's more like climbing stairs." She recommended revisiting protein intake, hydration, sleep, and daily movement as tools for pushing through a plateau. She also floated the idea that a stalled scale might reflect muscle gain or water retention, not failure. She openly shared that she has personally been in a stall for "the past couple of months."

This is practical, experience-based advice from someone with significant personal stakes in the topic. She is not claiming a cure, not recommending doses, and not selling anything obvious. That context matters when evaluating what she got right and what she glossed over.

Does the science back this up?

Mostly, yes. Weight loss plateaus on GLP-1 receptor agonists are well-documented and have a real physiological basis, not just a motivational slump. The stair-step analogy she uses is a reasonable lay description of what researchers see in trial data.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that semaglutide produces the most rapid weight loss in the first several months, with the rate slowing considerably by week 60. Participants continued losing weight but at a reduced pace, which looks like a plateau in the short term. Similarly, the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) for tirzepatide showed a comparable deceleration pattern. These slowdowns are not anomalies; they are built into how the drugs work.

Her suggestions about protein, sleep, and movement are also grounded in evidence. Leidy et al. (2015, American Journal of Clinical Nutrition) found that higher protein diets support satiety and lean mass preservation during caloric restriction, both of which matter during a plateau.

What did they get wrong, or right?

She got the general picture right but let a common misconception slide through unchallenged. The idea that "you might be building muscle" during a scale stall is, for most people in a significant caloric deficit, not a strong explanation. Simultaneous muscle gain and fat loss, sometimes called body recomposition, does happen, but it is much more likely in people who are new to resistance training or returning after a break, not in someone 275 pounds into a long weight loss journey.

Research by Barakat et al. (2020, Strength and Conditioning Journal) confirms that recomposition is real but context-dependent. Using it as a blanket reassurance for a two-month stall could cause someone to miss a real issue, like a dose that needs adjustment or a meaningful uptick in calorie intake.

Water retention as an explanation for a short plateau, however, is entirely plausible and underappreciated. Hormonal fluctuations, increased carbohydrate intake, or a new exercise routine can all trigger temporary fluid shifts that mask fat loss on the scale. That part of her explanation is solid.

What should you actually know?

If you are on a GLP-1 medication and the scale has not moved in several weeks, there are a few things worth knowing before you assume it is just "your body adjusting."

• GLP-1 medications can lose some appetite-suppressing effect over time if a dose is not titrated appropriately. A two-month stall is a reasonable trigger to have a conversation with your prescriber, not just to revisit your habits.
• Calorie creep is real and well-documented. Dansinger et al. (2005, JAMA) found that self-reported dietary adherence was the single strongest predictor of weight loss outcomes across multiple diet plans, and most people underestimate their intake over time.
• The stair-step model she describes does reflect real physiology. Adaptive thermogenesis, where your body reduces energy expenditure in response to weight loss, is documented in research by Rosenbaum and Leibel (2010, Journal of Clinical Investigation). Your metabolism slows as you lose weight, and GLP-1 drugs do not fully override that.
• Sleep is not a soft suggestion. Spiegel et al. (2004, Annals of Internal Medicine) showed that even modest sleep restriction significantly alters hunger hormones, specifically raising ghrelin and lowering leptin, which can undermine appetite control that GLP-1 drugs are partly providing.

The bottom line: her advice is reasonable as far as it goes. But a multi-month stall deserves a clinical conversation, not just a motivational reset.